News Archive

News Category Author

Dec 13, 2017

Guest Commentary: The Tipping Point

Payers will be buying the way other industrial buyers do -- they'll comparison shop. It's crucial that biopharma provide them the appropriate measurement tools. If they don't, buyers will settle on the easiest point of comparison: price.

read full article ›

Dec 13, 2017

The Shrinking Value Of Best-In-Class And First-In-Class Drugs

It’s the Planck constant of the pharmaceutical industry: if you’re going to build a commercially successful drug, it needs to

read full article ›

Dec 13, 2017

Guest Commentary: Overvaluing Speed to Market

Paying a lot of money to get your drug to market first is, in most cases, going to be worth a lot less in a payer-engaged future than it was in the physician-dominated past.

read full article ›

Dec 13, 2017

Overcoming the Political and Economic Roadblocks Stopping Effective Comparative Drug Evaluation

Transparent comparative evaluations are necessary for determining the relative value of drugs. But, in part because of resistance from drug companies and payers, stakeholders are finding other tools to help identify the appropriate choices.

read full article ›

Dec 13, 2017

The “Myth” of the Payer

Not all payers make their decisions the same way. Smart payer segmentation strategies are extremely important to successful biopharmas.

read full article ›

Dec 13, 2017

Smart Segmentation/ Success In The Payer-Dominated Pharma Marketplace

As physicians lose decision-making authority to payers, drug companies need to segment markets more effectively: the patient populations prescribers are most likely to treat and that will spark the fewest access battles; and the specific payer lines-of-business least inclined to block new drugs’ use.

read full article ›

Dec 13, 2017

Contracting 2.0: The Why, When, How — And Why Not — Of Value-Based Deals

Learn why are we are seeing increasing numbers of value-based deals in the industry, how they are structured and when they make sense.

read full article ›